Taylor Hoffman Wealth Management Buys 1,202 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Taylor Hoffman Wealth Management lifted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 13.5% during the 3rd quarter, Holdings Channel reports. The fund owned 10,117 shares of the biopharmaceutical company’s stock after acquiring an additional 1,202 shares during the quarter. Taylor Hoffman Wealth Management’s holdings in Bristol-Myers Squibb were worth $513,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bath Savings Trust Co lifted its holdings in Bristol-Myers Squibb by 3.4% during the 2nd quarter. Bath Savings Trust Co now owns 17,108 shares of the biopharmaceutical company’s stock worth $776,000 after buying an additional 568 shares in the last quarter. Boltwood Capital Management lifted its holdings in Bristol-Myers Squibb by 1.9% during the 2nd quarter. Boltwood Capital Management now owns 21,626 shares of the biopharmaceutical company’s stock worth $981,000 after buying an additional 400 shares in the last quarter. Thomasville National Bank lifted its holdings in Bristol-Myers Squibb by 1.6% during the 2nd quarter. Thomasville National Bank now owns 18,605 shares of the biopharmaceutical company’s stock worth $843,000 after buying an additional 293 shares in the last quarter. Private Asset Management Inc. lifted its holdings in Bristol-Myers Squibb by 5.5% during the 2nd quarter. Private Asset Management Inc. now owns 129,289 shares of the biopharmaceutical company’s stock worth $5,863,000 after buying an additional 6,775 shares in the last quarter. Finally, ELM Advisors LLC lifted its holdings in Bristol-Myers Squibb by 5.7% during the 2nd quarter. ELM Advisors LLC now owns 7,358 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 400 shares in the last quarter. 80.40% of the stock is currently owned by institutional investors and hedge funds.

BMY has been the topic of several research reports. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective on the stock in a report on Wednesday, August 14th. JPMorgan Chase & Co. set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, September 13th. Wolfe Research set a $66.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. Bank of America started coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $56.64.

BMY stock traded up $0.44 during trading hours on Friday, reaching $58.02. 11,418,626 shares of the stock were exchanged, compared to its average volume of 12,766,524. The firm’s 50-day moving average is $52.90 and its 200-day moving average is $48.19. The company has a market cap of $91.88 billion, a price-to-earnings ratio of 14.58, a PEG ratio of 1.31 and a beta of 0.71. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $58.46.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.11. The firm had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 EPS. As a group, equities research analysts forecast that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date of this dividend was Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

In other news, insider Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the transaction, the insider now owns 31,963 shares in the company, valued at approximately $1,807,827.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the transaction, the senior vice president now owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.